靶向治疗：改善转移性黑色素瘤患者的预后。
Targeted therapies: Improved outcomes for patients with metastatic melanoma.
机构信息
Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA.
出版信息
Nat Rev Clin Oncol. 2011 Jul 26;8(9):513-5. doi: 10.1038/nrclinonc.2011.119.
PMID:21788973
Abstract
Recently published phase III trials involving interleukin-2, ipilimumab and vemurafenib redefine 'standard-of-care' for metastatic melanoma and demonstrate improved survival compared with dacarbazine. All three therapies are potential first-line options for patients with metastatic melanoma, with optimal treatment strategies evolving based on tumor mutation status, disease burden, performance status and comorbidities.
摘要
最近发表的涉及白细胞介素-2、伊匹单抗和维莫非尼的 III 期临床试验重新定义了转移性黑色素瘤的“标准治疗”，并与达卡巴嗪相比显示出改善的生存。所有这三种疗法都是转移性黑色素瘤患者的潜在一线选择，最佳治疗策略基于肿瘤突变状态、疾病负担、表现状态和合并症而不断发展。
Zotero 插件